| 2024 | Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
| 2024 | HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
| GASTROENTEROLOGY |
| 2024 | PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B | JOURNAL OF HEPATOLOGY |
| 2023 | Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
| JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION |
| 2023 | Association of Alcohol Consumption With Liver Cancer and All-Cause Mortality in Chronic Hepatitis B Patients Without Cirrhosis | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
| CELL COMMUNICATION AND SIGNALING |
| 2023 | Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2023 | Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
| JHEP REPORTS |
| 2023 | Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2023 | Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients | INTERNATIONAL JOURNAL OF CANCER |
| 2023 | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | How can we improve surveillance system for alcohol-associated hepatocellular carcinoma? | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B | LIVER INTERNATIONAL |
| 2023 | Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2023 | Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2023 | Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study | AMERICAN JOURNAL OF GASTROENTEROLOGY |
| 2023 | Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
| JHEP REPORTS |
| 2023 | The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2023 | Statin use is associated with better post-operative prognosis among patients with hepatitis B virus-related hepatocellular carcinoma | EUROPEAN JOURNAL OF CLINICAL INVESTIGATION |
| 2023 | Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease | LIVER INTERNATIONAL |
| 2023 | CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B | JOURNAL OF DIGESTIVE DISEASES |
| 2023 | Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
| 2023 | Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study | EUROPEAN JOURNAL OF INTERNAL MEDICINE |
| 2023 | Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
| FRONTIERS IN ENDOCRINOLOGY |
| 2023 | Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
| DIAGNOSTICS |
| 2023 | Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
| HEPATOLOGY COMMUNICATIONS |
| 2023 | Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study
| INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH |
| 2023 | Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Dise | GUT AND LIVER |
| 2022 | Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
| HEPATOLOGY COMMUNICATIONS |
| 2022 | Liver Diseases in South Korea: A Pulse Check of the Public's Knowledge, Awareness, and Behaviors
| YONSEI MEDICAL JOURNAL |
| 2022 | New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
| CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY |
| 2022 | Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study | HEPATOLOGY RESEARCH |
| 2022 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B | LIVER INTERNATIONAL |
| 2022 | MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups | DIGESTIVE DISEASES AND SCIENCES |
| 2022 | Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
| CANCERS |
| 2022 | Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
| Journal of Liver Cancer(대한간암학회지) |
| 2022 | Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
| HEPATOLOGY COMMUNICATIONS |
| 2022 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
| GUT AND LIVER |
| 2022 | Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma | EUROPEAN JOURNAL OF INTERNAL MEDICINE |
| 2022 | Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study | DIABETES & METABOLISM |
| 2022 | Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis | ALIMENTARY PHARMACOLOGY & THERAPEUTICS |
| 2022 | Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
| GASTROENTEROLOGY REPORT |
| 2022 | Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B | DIGESTIVE DISEASES AND SCIENCES |
| 2022 | Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study | DIABETES & METABOLISM |
| 2022 | Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone | CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT |
| 2022 | Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B | LIVER INTERNATIONAL |
http://orcid.org/0000-0002-3629-4624
(7401989551)
